The activation of the PD-L1 and PD-1 complex is related to immunosuppression, and promotes tumor progression in various tumors, including renal cell carcinoma, esophageal cancer, stomach cancer, melanoma, and HNSCC (17, 23–25). This evidence concerns the gene PDCD1 and neoplasm.